Adocia (Adocia) Days Payable : 0.00 (As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Adocia Days Payable?

Adocia's average Accounts Payable for the six months ended in Jun. 2023 was $4.06 Mil. Adocia's Cost of Goods Sold for the six months ended in Jun. 2023 was $0.00 Mil.

The historical rank and industry rank for Adocia's Days Payable or its related term are showing as below:

ADOIF' s Days Payable Range Over the Past 10 Years
Min: 351.89 Med: 495.08 Max: 948.58
Current: 481.21

During the past 14 years, Adocia's highest Days Payable was 948.58. The lowest was 351.89. And the median was 495.08.

ADOIF's Days Payable is ranked better than
74.79% of 714 companies
in the Biotechnology industry
Industry Median: 146.16 vs ADOIF: 481.21

Adocia's Days Payable stayed the same from Jun. 2022 (0.00) to Jun. 2023 (0.00).

Adocia Days Payable Historical Data

The historical data trend for Adocia's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adocia Days Payable Chart

Adocia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

683.68

607.54

535.62

488.48

Adocia Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Adocia's Days Payable

For the Biotechnology subindustry, Adocia's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adocia's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adocia's Days Payable distribution charts can be found below:

* The bar in red indicates where Adocia's Days Payable falls into.

Adocia Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Adocia's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (1.234	+	3.98)	/	2 )	/	1.948	*	365
=	2.607					/	1.948	*	365
=	488.48

Adocia's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (3.98	+	4.143)	/	2 )	/	0	*	365 / 2
=	4.0615					/	0	*	365 / 2
=	N/A

Adocia Days Payable Related Terms

Thank you for viewing the detailed overview of Adocia's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Adocia (Adocia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adocia (OTCPK:ADOIF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ADOC:France A89:Germany

Address

115 Avenue Lacassagne, Lyon, FRA, 69003

Website

https://www.adocia.com

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.